3032493-76-5

Anticancer agent 340 Chemical Structure
3032493-76-5

Chemical Structure

Anticancer agent 340

  • CAS No.: 3032493-76-5
  • Formula:C49H51ClN10O4S
  • Molecular Weight:911.51

InChIKey: MFQCZZWWLAYIPM-ZCTOLVMZSA-N

SMILES: CC(C)([C@H](C1(C)C)OC2=CC(Cl)=C(C=C2)C#N)[C@H]1NC(C3=CN=C(N=C3)N(CC4)CCC4(C5)CC5OC6=CC=C(C7=N[C@@H](CC8=NC=CO8)C9=NN=C(C)N9C%10=C7C(C)=C(C)S%10)C=C6)=O

Biological Activity: Anticancer agent 340 is an orally active antitumor agent. Anticancer agent 340 can bind to both the androgen receptor (AR) and BRD4 protein simultaneously, dose-dependently inducing the formation of the AR-BRD4 ternary complex, inhibiting the expression of the downstream target gene HEXIM1 (Gene X), and activating the Caspase 3/7 pathway to initiate apoptosis. Its proliferation inhibition and apoptosis activities are both significantly AR expression-dependent. Anticancer agent 340 can be used to study AR/BRD4 driven malignancies such as castration-resistant prostate cancer (CRPC)[1].

Cat. No. Product Name Purity Description Pricing
HY-184865
Anticancer agent 340 Anticancer agent 340 is an orally active antitumor agent. Anticancer agent 340 can bind to both the androgen receptor (AR) and BRD4 protein simultaneously, dose-dependently inducing the formation of the AR-BRD4 ternary complex, inhibiting the expression of the downstream target gene HEXIM1 (Gene X), and activating the Caspase 3/7 pathway to initiate apoptosis. Its proliferation inhibition and apoptosis activities are both significantly AR expression-dependent. Anticancer agent 340 can be used to study AR/BRD4 driven malignancies such as castration-resistant prostate cancer (CRPC).
Pricing 
Expand Hide
loading...
/
  • /
loading...
Size Price
Stock Quantity Availability Operate
/
In-stock
(Estimated to ship on )
(Estimated to ship TODAY)
Estimated to ship on
(Estimated to ship TODAY)

Amount:

USD 0.00

This product is a controlled substance and not for sale in your territory.

This product is not for sale in your territory.

Pricing 
Expand Hide
References